Patent ID: 8530162

Claim:
An in vitro method for establishing a prognosis concerning a patient suffering from acute myleoid leukaemia, comprising: isolating peripheral blood mononucleated cells from a blood sample from said patient; extracting RNA from said peripheral blood mononucleated cells; measuring the level of VEGF121 transcript in said peripheral blood mononucleated cells a real-time quantitative reverse transcription-polymerase chain reaction (QRT-PCR), wherein the first primer used for amplification comprises at least 15 consecutive nucleotides from exon 4, and wherein the second primer spans the junction between exons 5 and 8 and comprises at least a sequence complementary to the sequence 5′- GAAAAATGTGAC-3′ (SEQ ID No: 8); and determining a prognosis based on the level of VEGF121.